A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
- By:
- Publication type:
- Article